Overview

Study of BMS-986453 in Newly Diagnosed Multiple Myeloma

Status:
NOT_YET_RECRUITING
Trial end date:
2043-01-01
Target enrollment:
Participant gender:
Summary
This is a phase 1b study evaluating if BMS-986453 is safe and effective in treating people who have newly diagnosed multiple myeloma after completing initial therapy (induction) when a stem cell transplant is not intended.
Phase:
PHASE1
Details
Lead Sponsor:
Susan Bal
Collaborator:
Bristol-Myers Squibb